LILRB1 and breast carcinoma: We observed that the HLA-G- or KIR2DL4-neutralizing antibody, but not the ILT2 antibody, significantly increased IFN-γ production by NK cells cocultured with breast cancer cells in the presence of trastuzumab (Fig. 2c and Supplementary Fig. S6b).